-- EU regulator backs drugs from Bayer, GSK, knocks back Novartis 
-- 
-- Fri Jan 24, 2014 07:22AM EST
-- None



LONDON, Jan 24 (Reuters) - European drugs regulators gave their backing on Friday for marketing authorisations to be granted for Bayer's <BAYGn.DE> drug Adempas, designed to treat pulmonary hypertension, and for GlaxoSmithKline's <GSK.L> diabetes medicine Eperzan.

The regulator also backed a new drug from Dainippon Sumitomo Pharma <4506.T> called Latuda, for the treatment of schizophrenia, and Bemfola, a new biosimilar medicine for the treatment of infertility.